Stabilizing and delivering oxygen for targeted clinical indications

Respirogen, Inc. is focused on developing innovative therapeutic solutions for oxygen delivery, particularly targeting conditions such as Acute Respiratory Distress Syndrome (ARDS). This severe lung disease, often seen in intensive care settings, leads to significant breathing difficulties and is associated with high mortality rates. Respirogen's technology aims to stabilize and deliver oxygen directly to the bloodstream, bypassing the damaged lungs, which could reduce the reliance on invasive treatments like ventilators and Extracorporeal Membrane Oxygenation (ECMO). The company highlights the urgent need for effective therapies in this area, given the substantial number of patients affected annually.

The core of Respirogen's technology is the use of Oxygen Microbubbles (OMBs), which are stabilized oxygen gas spheres designed for sterile delivery. These microbubbles can provide systemic oxygenation, even in patients with compromised lung function. The precise control over their size and composition allows for effective oxygen delivery, which is crucial in preventing organ damage due to hypoxia. Additionally, the OMBs are characterized by their stability, ease of transport, and cost-effectiveness, making them a promising option for various clinical applications. Ongoing research collaborations with institutions like the University of Nebraska and the University of Colorado, supported by U.S. Air Force grants, further emphasize the potential of this technology in both medical and consumer product markets.

United States

Respirogen's technology will provide oxygen independent from damaged lungs. Acute respiratory distress syndrome (ARDS) is an acute severe lung disease commonly encountered in intensive care units (ICU). It can be caused by several triggers, including pneumonia or trauma. It is characterized by widespread injury of the alveolar–capillary membrane, resulting in protein rich noncardiogenic pulmonary edema (fluid accumulation in the lungs) and acute respiratory failure (ARF). ARDS results in severe  hypoxaemia, which is refractory to oxygen treatment and requires assisted ventilation.

Respirogen

Company Details